Effect of a specific dopaminergic blocking agent, pimozide, on hypothalamic corticotropin-releasing-factor activity in rats: Clinical correlates

1975 ◽  
Vol 31 (2) ◽  
pp. 249-250 ◽  
Author(s):  
G. Virgina Upton ◽  
A. Corbin
Keyword(s):  
Blocking Agent ◽  
Corticotropin Releasing Factor ◽  
Factor Activity ◽  
Clinical Correlates ◽  
Dopaminergic Blocking

ASSAYS AND DYNAMICS OF CORTICOTROPIN-RELEASING FACTOR ACTIVITY IN RAT HYPOTHALAMUS

1977 ◽  
Vol 297 (1 ACTH and Rela) ◽  
pp. 436-454 ◽  
Author(s):  
T. Hiroshige ◽  
K. Fujieda ◽  
M. Kaneko ◽  
K. Honma
Keyword(s):  
Corticotropin Releasing Factor ◽  
Factor Activity ◽  
Rat Hypothalamus

DIENCEPHALIC INVOLVEMENT IN GENERALIZED LIPODYSTROPHY: RATIONALE AND TREATMENT WITH THE NEUROLEPTIC AGENT, PIMOZIDE

1974 ◽  
Vol 77 (2) ◽  
pp. 209-220 ◽  
Author(s):  
Alan Corbin ◽  
G. Virginia Upton ◽  
C. C. Mabry ◽  
Dorothy R. Hollingsworth
Keyword(s):  
General Circulation ◽  
Subcutaneous Fat ◽  
Well Being ◽  
Blood Chemistry ◽  
Peripheral Circulation ◽  
Blocking Agent ◽  
Corticotrophin Releasing Factor ◽  
Neuroleptic Agent ◽  
Catecholaminergic Mechanisms ◽  
Dopaminergic Blocking

ABSTRACT Our results indicate that generalized lipodystrophy (GLD) possesses as one of its manifestations, diencephalic neuroendocrinopathy. It has been postulated that deranged hypothalamic catecholaminergic mechanisms lead to the hypersecretion of hypophysiotrophic hormones that are detectable in the peripheral circulation. Initial treatment of a pre-puberal GLD patient with chlorpromazine was unrewarding. Chronic treatment of the same patients with the selective dopaminergic blocking agent, pimozide, eliminated corticotrophin releasing factor and luteinizing hormone releasing factor activities from the general circulation. Pimozide treatment ameliorated most of the distorted blood chemistry profile, led to return of facial subcutaneous fat, and elimination of cutaneous hyperpigmentation, fever, abdominal pain, hypertrichosis, oilness of hair, scaliness of skin and to a state of general well-being. The results of these studies, structured within the framework of our present knowledge concerning hypothalamic neurotransmitter/releasing hormone physiology, support the concept of diencephalic involvement in GLD and may provide a guideline to effective therapy.

scholarly journals High molecular weight peptide with corticotropin-releasing factor activity from porcine hypothalami.

1981 ◽  
Vol 78 (8) ◽  
pp. 5197-5201 ◽  
Author(s):  
A. V. Schally ◽  
R. C. Chang ◽  
A. Arimura ◽  
T. W. Redding ◽  
J. B. Fishback ◽  
...  
Keyword(s):  
Molecular Weight ◽  
High Molecular Weight ◽  
Corticotropin Releasing Factor ◽  
Factor Activity

scholarly journals Purification and characterization of peptides with corticotropin-releasing factor activity from porcine hypothalami.

1986 ◽  
Vol 83 (9) ◽  
pp. 2969-2973 ◽  
Author(s):  
M. Patthy ◽  
D. H. Schlesinger ◽  
J. Horvath ◽  
M. Mason-Garcia ◽  
B. Szoke ◽  
...  
Keyword(s):  
Corticotropin Releasing Factor ◽  
Factor Activity ◽  
Purification And Characterization

Characterization of corticotropin-releasing factor activity from sheep hypothalamic extracts

Life Sciences ◽  
1981 ◽  
Vol 28 (24) ◽  
pp. 2761-2768
Author(s):  
Marian Jutisz ◽  
Jacob Kraicer ◽  
Geneviève Ribot
Keyword(s):  
Corticotropin Releasing Factor ◽  
Factor Activity

scholarly journals GENERALIZED LIPODYSTROPHY: EFFECT OF CEREBRAL DOPAMINERGIC BLOCKING AGENT (PIMOZIDE)

1974 ◽  
Vol 8 (4) ◽  
pp. 435-435
Author(s):  
C C Mabry ◽  
G V Upton ◽  
A Corbin ◽  
D R Hollingsworth
Keyword(s):  
Blocking Agent ◽  
Dopaminergic Blocking
Sign in / Sign up

Export Citation Format

Share Document